December 7, 2022 – Newswire – Vancouver, British Columbia – Roadman Investments Corp. (TSX-V: LITT) (“Roadman” or the “Company”) is pleased to announce that it has made an investment in 1254571 BC Ltd. (the “Investee”).

The Investee is a company that has the ability and licensing to produce Good Manufacturing Practices (“GMP”) grade products using controlled substances. The fully equipped laboratory the Investee is operating in is designed specifically for the production of pharmaceutical drugs. The laboratory holds: (i) a Canadian issued Narcotics license; (ii) a Health Canada GMP facility license; and (iii) an American Food and Drug Administration facility registration. These licenses and registrations allow the Investee to conduct research, as well as formulate, produce and export psychedelic compounds.

In addition, the Investee has a partnership with a British Columbia, Canada-based compounding pharmacy that has been operating for 15 years. The compounding pharmacy has licenses for controlled substances and extensive experience formulating various drug compounds. On December 7, 2022, the Company purchased 16,186 common shares of the Investee (each, a “Share”) at a price of $12.36 per Share by way of private placement for an aggregate purchase price of $200,000.

About Roadman Investments Corp.

Roadman Investments Corp. is a Canadian Venture Capital, Investment and Advisory Firm that strives to actively drive innovation and accelerate growth for its shareholders. Roadman invests capital into private and public companies that offer excellent growth opportunities.


Tyler Lewis


Cautionary and Forward-Looking Statements

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this release.